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Protocol
AbstrACt
Introduction WHO recommends the use of pneumococcal 
conjugate vaccine (PCV) as a priority. However, there 
are many countries yet to introduce PCV, especially in 
Asia. This trial aims to evaluate different PCV schedules 
and to provide a head-to-head comparison of PCV10 
and PCV13 in order to generate evidence to assist with 
decisions regarding PCV introduction. Schedules will be 
compared in relation to their immunogenicity and impact 
on nasopharyngeal carriage of Streptococcus pneumoniae 
and Haemophilus influenzae.
Methods and analysis This randomised, single-blind 
controlled trial involves 1200 infants recruited at 2 
months of age to one of six infant PCV schedules: PCV10 
in a 3+1, 3+0, 2+1 or two-dose schedule; PCV13 in a 
2+1 schedule; and controls that receive two doses of 
PCV10 and 18 and 24 months. An additional control group 
of 200 children is recruited at 18 months that receive one 
dose of PCV10 at 24 months. All participants are followed 
up until 24 months of age. The primary outcome is the 
post-primary series immunogenicity, expressed as the 
proportions of participants with serotype-specific antibody 
levels ≥0.35 µg/mL for each serotype in PCV10.
Ethics and dissemination Ethical approval has been 
obtained from the Human Research Ethics Committee 
of the Northern Territory Department of Health and 
Menzies School of Health Research (EC00153) and the 
Vietnam Ministry of Health Ethics Committee. The results, 
interpretation and conclusions will be presented to parents 
and guardians, at national and international conferences, 
and published in peer-reviewed open access journals.
trial registration number NCT01953510; Pre-results.
IntroduCtIon 
background and rationale
Streptococcus pneumoniae (pneumococcus) 
remains a leading vaccine preventable cause 
of serious infection in young children, despite 
the availability of effective vaccines. The first 
infant pneumococcal vaccine, the 7-valent 
pneumococcal conjugate vaccine (PCV7), 
was licensed in the USA in the year 2000. 
Introduction of PCV7 has been associated 
with dramatic reductions in pneumococcal 
disease.1–3 However, geographical variation 
in serotype distribution4–7 and an increase in 
invasive pneumococcal disease (IPD) caused 
by non-PCV7 serotypes following vaccine 
introduction8 necessitated the development 
of higher valency PCVs.
There are currently two licensed PCVs: 
PCV10, a 10-valent pneumococcal vaccine 
that uses non-typeable Haemophilus influenzae 
(NTHi) protein D as a carrier protein for 8 of 
the 10 serotypes (Synflorix, PHiD-CV; GSK); 
and PCV13, a 13-valent pneumococcal CRM197 
conjugate vaccine (Prevnar-13/Prevenar-13; 
Pfizer). Both have been shown to be non-in-
ferior to PCV7 in terms of post-primary series 
immunogenicity for the shared serotypes.9–11 
strengths and limitations of this study
 ► This study is specifically designed to address two 
independent questions within a single study: which 
schedule to use for the provision of pneumococ-
cal conjugate vaccine (PCV), and which PCV to use.
 ► This study includes a head-to-head comparison of 
the two licensed PCVs, allowing a direct assessment 
of their relative immunogenicity and impact on na-
sopharyngeal carriage.
 ► The primary outcome is the criteria used for the li-
censing and varying of PCV schedules.
 ► This study has relatively low power for the second-
ary nasopharyngeal carriage outcomes, so the abil-
ity to draw conclusions relating to these outcomes 
is vulnerable in the event of lower-than-anticipated 
carriage rates.
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Despite the availability of both PCV10 and PCV13 for 
several years, there have been no published studies to 
date directly comparing their post-primary series immu-
nogenicity or impact on nasopharyngeal (NP) carriage.
The cost of PCVs is a major barrier to vaccine introduction 
in low-income to middle-income countries; therefore, inves-
tigation of alternative schedules with a reduced number of 
doses is of great importance. The uptake of PCV introduc-
tion in Asia has been particularly slow. Three schedules are 
currently in routine use around the world for PCV introduc-
tion: a 3+1 schedule (a three-dose primary series followed 
by a booster dose in the second year of life), a 3+0 schedule 
(a three-dose primary series without a booster dose) and 
a 2+1 schedule (a two-dose primary series followed by a 
booster dose in the second year of life). Data from periods 
of PCV7 shortage in the USA show high vaccine effective-
ness of a two-dose primary series against IPD,12 13 and trial 
data of CRM197-conjugated PCVs show comparable immu-
nogenicity following a two-dose or three-dose primary 
series, although antibody levels to serotypes 6B and 23F 
tend to be lower after two doses.14 15 Trials of PCV10 and 
PCV13 also support the use of a two-dose primary series. A 
trial of PCV10 in Europe directly comparing the immuno-
genicity of a two-dose and three-dose primary series showed 
a similar proportion of participants achieving protective 
antibody levels (≥0.2 µg/mL) for all 10 serotypes.16 In a 
trial of PCV13 in Mexico, over 93% of participants achieved 
protective antibody levels (≥0.35 µg/mL) for most of the 13 
serotypes following two doses, with the exception of sero-
types 6B and 23F.17 Four trials in Europe directly comparing 
PCV13 and PCV7 responses showed comparable immune 
responses between the vaccines following two doses.18
In developing countries, a 2+1 schedule with a booster 
dose in the first year of life may be advantageous. This 
modified schedule would likely increase compliance, would 
provide full immunisation closer to the peak incidence of 
pneumococcal disease and could enable the booster dose 
to coincide with measles vaccination. Alternatively, a further 
reduced PCV schedule with only two doses may be optimal 
for pneumococcal vaccination. Our previous trial in Fiji 
showed that protective antibody levels were reached for five 
of the seven serotypes following a single dose of PCV7 at 14 
weeks of age.15 Furthermore, a booster dose of the 23-valent 
pneumococcal polysaccharide vaccine at 12 months of age 
was more immunogenic following a single dose primary 
series of PCV7 compared with a two-dose or three-dose 
primary series for four serotypes, and comparable for the 
other three serotypes.19 A trial of PCV9 from South Africa 
also showed that one dose at 6 weeks of age elicited a signif-
icant response for seven serotypes,20 and modelling data 
from the USA suggest that a single dose of PCV could 
prevent up to 62% of IPD.21 More recently, in the UK, 
where routine infant PCV vaccination has been in place for 
over 10 years, a 1+1 schedule of PCV13 was shown to elicit 
equivalent or superior post-booster responses compared 
with a 2+1 schedule for nine serotypes.22
Carriage of pneumococci in the nasopharynx is 
commonly a prerequisite for IPD and is the usual means 
of transmission of the bacteria. The herd effect of pneu-
mococcal vaccination is mediated by the impact on NP 
carriage.23 Vaccination with PCVs generally results in a 
decrease in vaccine type (VT) pneumococcal carriage, 
which is most commonly observed after a booster dose 
and often accompanied by a compensatory increase in 
non-VT carriage.23–27 There have been few trials that eval-
uate the effect of different PCV schedules on carriage. A 
trial from the Netherlands showed that a two-dose primary 
series with or without a booster reduced VT carriage at 12 
months of age compared with controls.28 VT carriage was 
further reduced at 18 months in the group that received 
the booster dose, compared with the group that did not 
receive the booster, although this difference did not persist 
at 24 months of age. Similarly, our trial in Fiji showed that 
a two-dose or three-dose primary series with or without a 
booster reduced VT carriage at 12 months of age compared 
with controls, but no difference was seen at 17 months of 
age (F Russell, personal communication).
It has been hypothesised that the protein D carrier in 
PCV10 may result in an impact on H. influenzae carriage. A 
recent review of the impact of protein D-containing PCVs 
on NTHi carriage concludes that any such impact is likely 
to be small and transient, although changes in the density 
of carriage are yet to be evaluated. Two large phase III 
trials (POET trial of an 11-valent PCV and COMPAS trial 
of PCV10) showed trends towards a reduction in NTHi 
carriage following a booster dose of PCV, along with a trial 
of PCV10 in toddlers in Kenya, but other trials conducted in 
Finland, the Netherlands and the Czech Republic showed 
no impact of PCV10 on NTHi carriage.29
This trial includes six infant vaccination schedules: four 
different PCV10 schedules (arm A, a 3+1 schedule at 2, 3, 
4 and 9 months of age; arm B, a 3+0 schedule at 2, 3 and 
4 months; arm C, a 2+1 schedule at 2, 4 and 9.5 months; 
and arm D, a two-dose schedule at 2 and 6 months); a 2+1 
PCV13 schedule at 2, 4 and 9.5 months (arm E); and a 
control group that receives two doses of PCV10 at 18 and 
24 months (arm F). In response to more recent interest in 
schedules with only one or two doses of PCV, which may 
be sufficient to maintain herd immunity at the population 
level, an additional control group is recruited at 18 months 
of age for comparison with the initial control group (arm 
G).
Explanation for choice of comparators
There was no PCV licensed in Vietnam at the time the 
protocol was finalised in 2013. The inclusion of control 
groups that receive no infant doses of PCV is therefore 
justified. Control group participants recruited in infancy 
receive two doses of PCV10, at 18 and 24 months of age. 
Control group participants recruited at 18 months of age 
receive a single dose of PCV10 at 24 months of age. Inter-
vention group participants receive at least two doses of 
PCV in the first year of life. All participants receive pneu-
mococcal immunisation that is likely to be effective and 
is not otherwise available in Vietnam. The specific regi-
mens to be evaluated are based on likely future global 
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recommendations and to directly compare the two 
licensed PCVs.
Both PCV10 and PCV13 have been shown to be non-in-
ferior to PCV7 for the serotypes common to both vaccines, 
and to have the potential to provide protection against 
the additional serotypes included.9–11 For both vaccines, 
the most common adverse reactions are redness at the 
injection site and irritability, which are common following 
administration of other vaccines. Other adverse reactions 
may include drowsiness; temporary loss of appetite; pain, 
redness or swelling at the injection site; and fever. Such 
reactions are usually temporary.
objECtIvEs
This trial has been designed to answer two indepen-
dent questions concurrently, relating to the evaluation 
of different schedules incorporating PCV10 and the 
comparison of PCV10 and PCV13:
1. What is the optimal schedule for provision of EPI vac-
cines with the incorporation of PCV10; and
2. How do the responses to vaccination with PCV10 or 
PCV13 compare?
The primary endpoint for both study questions is the 
post-primary series immunogenicity. For this endpoint, 
data from arms A and B are combined, as they receive 
an identical three-dose primary series (see table 1 for a 
detailed description of the trial arms). The primary anal-
ysis for each study question is to assess non-inferiority of 
the post-primary series immunogenicity (in terms of the 
proportion of participants achieving protective levels of 
serotype-specific IgG of ≥0.35 µg/mL), using arms A+B as 
the comparator (see below for details). Non-inferiority is 
assessed for each of the 10 serotypes in PCV10, and an 
overall conclusion of non-inferiority drawn if found for at 
least 7 of the 10 serotypes.
What is the optimal schedule for provision of Expanded 
Program of Immunisation (EPI) vaccines with the 
incorporation of PCv10?
Primary objective
The primary objective is to compare a 2+1 schedule at 2, 
4 and 9.5 months of age with a 3+1 schedule at 2, 3, 4 
and 9 months of age. The primary hypothesis is that the 
proportion of participants with protective levels of anti-
body is non-inferior following a two-dose primary series 
Table 1 Schedule of enrolment, interventions and assessments
Age (months) 2 3 4 5 6 7 9 9.5 10 12 18 19 24
Enrolment
  Informed consent X X*
  Eligibility assessment X X*
  Allocation X
Interventions
  PCV10—group A X X X X
  PCV10—group B X X X
  PCV10—group C X X X
  PCV10—group D X X
  PCV13—group E X X X
  PCV10—group F X X
  PCV10—group G X
Assessments
  Demographics X X*
  Household characteristics X X*
  Nasopharyngeal swab X X X X X X
  Blood sample—group A X† X X X X†
  Blood sample—group B X X X† X X†
  Blood sample—group C X X† X X X†
  Blood sample—group D X X X X† X†
  Blood sample—group E X† X X X X†
  Blood sample—group F X X X
  Blood sample—group G X X X
  General health X X X X X X X X X X X X X
*Group G only. Any events occurring before 18 months do not apply to group G.
†Each participant provides only one of these blood samples (the last 50 participants per group enrolled into groups A–E provide this blood 
sample at 18 months; the remainder provide it at the other time point).
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(arm C) compared with a three-dose primary series (arms 
A+B). The schedules will also be compared in relation 
to the geometric mean concentrations (GMCs) of IgG 
and opsonophagocytosis post-primary series; the propor-
tion of participants with protective levels of antibody, the 
GMCs of IgG and opsonophagocytosis post-booster; the 
memory B-cell responses; and the impact on nasopharyn-
geal (NP) carriage rates and density of bacteria of interest.
Key secondary objectives
 ► To investigate an experimental two-dose schedule 
at 2 and 6 months of age (arm D), compared with 
a 3+1 schedule (arm A±B) and a 2+1 schedule (arm 
C); and
 ► To assess the impact of a booster dose on NP carriage of 
pneumococcus and NTHi, comparing a 3+1 schedule 
(arm A) with a 3+0 schedule (arm B) and with unvac-
cinated controls (arm F).
How do the responses to vaccination with PCv10 or PCv13 
compare?
Primary objective
The primary objective is to compare a PCV13 schedule at 
2, 4 and 9.5 months of age with a PCV10 schedule at 2, 3, 
4 and 9 months of age. The primary hypothesis is that the 
proportion of participants with protective levels of anti-
body is non-inferior following a two-dose primary series 
of PCV13 (arm E) compared with a three-dose primary 
series of PCV10 (arms A+B). The schedules will also be 
compared in relation to the GMCs of IgG and opsono-
phagocytosis post-primary series; the proportion of 
participants with protective levels of antibody, the GMCs 
of IgG and opsonophagocytosis post-booster; the memory 
B-cell responses; and the impact on nasopharyngeal (NP) 
carriage rates and density of bacteria of interest.
Key secondary objectives
 ► To compare PCV10 (arm C) and PCV13 (arm E) in a 
2+1 schedule at 2, 4 and 9.5 months of age; and
 ► To compare the responses to a single dose of PCV10 
(arm D) and PCV13 (arm E).
Additional objectives
Additional objectives relating to the second control group 
(arm G) are:
 ► To evaluate a single dose of PCV10 at 18 months of 
age, comparing serotype-specific antibody levels in 
arms F and G at 18, 19 and 24 months of age; and
 ► To compare the immunogenicity and reactogenicity 
of Infanrix-hexa at 18 months of age in children who 
have received three doses of Infanrix-hexa or Quin-
vaxem in infancy (arm G).
trial design
The Vietnam Pneumococcal Project is a single-blind, 
open-label, randomised controlled phase II/III non-in-
feriority trial to investigate simplified childhood vaccina-
tion schedules that are more appropriate for developing 
country use. This is a seven-arm trial that includes six 
different infant vaccination schedules (arms A–F) and an 
additional control group (arm G) recruited at 18 months 
of age (table 1). Arm A receives PCV10 at 2, 3, 4 and 9 
months of age (3+1); arm B receives PCV10 at 2, 3 and 
4 months (3+0); arm C receives PCV10 at 2, 4 and 9.5 
months (2+1); arm D receives PCV10 at 2 and 6 months 
(two-dose); arm E receives PCV13 at 2, 4 and 9.5 months 
(2+1); arm F receives two doses of PCV10 at 18 and 24 
months; and arm G receives one dose of PCV10 at 24 
months. Participants also receive Infanrix-hexa (DTP-Hib-
HBV-IPV) instead of the routine EPI vaccine Quinvaxem 
(DTP-Hib-HBV): four doses for participants in arms A–F 
and one dose for arm G participants.
MEtHods And AnAlysIs
study setting
PCV introduction in Asia has been slow, in part due to a lack 
of local or regional data on the effect of PCV. We selected 
the Southeast Asian country of Vietnam as the location for 
the trial as a country with a strong health system, a track 
record of conducting relevant clinical trials, and a Govern-
ment with strong interest both in the trial and in intro-
ducing PCV in the near future. Furthermore, trial results 
from Vietnam are likely to be considered as applicable to 
other countries in the region. This is the first trial involving 
infants to take place within Ho Chi Minh City, the largest city 
in Vietnam. The trial is conducted in two districts, District 4 
and District 7. Districts are divided into communes, each of 
which has a health centre that provides preventive health 
services including EPI immunisations, along with some 
primary healthcare services. The study is conducted in one 
commune health centre in each district, with participants 
drawn from the surrounding communes within that district.
Eligibility criteria
Inclusion criteria
Subjects must meet all of the following inclusion criteria in 
order to be eligible to participate: aged between 2 months 
and 2 months plus 2 weeks (arms A–F) or aged between 18 
months and 18 months plus 4 weeks (arm G); no signifi-
cant maternal or perinatal history; born at or after 36 weeks’ 
gestation; written informed consent from the parent/
legal guardian; lives within approximately 30 min of the 
commune health centre; anticipates living in the study 
area for the next 22 months (arms A–F) or 6 months (arm 
G); and received three doses of either Quinvaxem or Infan-
rix-hexa in infancy (arm G only).
Exclusion criteria
Subjects meeting any of the following exclusion criteria 
at baseline will be excluded from study participation: 
known allergy to any component of the vaccine; allergic 
or anaphylactic reaction to any previous vaccine; known 
immunodeficiency disorder; known HIV-infected mother; 
known thrombocytopenia or coagulation disorder; 
on immunosuppressive medication; administration or 
planned administration of any immunoglobulin or blood 
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product since birth; severe birth defect requiring ongoing 
medical care; chronic or progressive disease; seizure 
disorder; history of invasive pneumococcal, meningo-
coccal or H. influenzae type b diseases, or tetanus, measles, 
pertussis or diphtheria infections; receipt of any 2-month 
vaccines through the EPI programme (arms A–F), or 
receipt of PCV (arm G); or family plans on giving the 
infant Quinvaxem (arms A–F).
Interventions
PCV schedules
Eligible participants recruited in infancy are randomised 
to one of six different vaccination schedules (table 1). 
Participants randomised to arms A–D receive PCV10 in a 
3+1 schedule at 2, 3, 4 and 9 months of age; a 3+0 schedule 
at 2, 3 and 4 months of age; a 2+1 schedule at 2, 4 and 9.5 
months of age; or a two-dose schedule at 2 and 6 months 
of age, respectively. Participants randomised to arm E 
receive PCV13 in a 2+1 schedule at 2, 4 and 9.5 months of 
age. Control group participants receive PCV10 at 18 and 
24 months of age if randomised to arm F, or PCV10 at 24 
months of age if recruited to arm G at 18 months of age. 
PCV is administered by intramuscular injection into the 
anterolateral thigh in children less than 18 months old 
and in the deltoid muscle of the arm in children aged 18 
months and over. All vaccinations are performed by nurses 
specifically trained in infant vaccine administration.
PCV10
PCV10 (Synflorix) is a 10-valent pneumococcal polysac-
charide conjugate vaccine using protein D (a highly 
conserved surface protein from NTHi) as the main carrier 
protein. PCV10 is presented as a turbid white suspension 
in a two-dose phial. One dose consists of 0.5 mL of the 
liquid vaccine, containing 1 µg of pneumococcal polysac-
charide from serotypes 1, 5, 6B, 7F, 9V, 14 and 23F and 
3 µg of pneumococcal polysaccharide from serotypes 4, 
18C and 19F. Serotypes 1, 4, 5, 6B, 7F, 9V, 14 and 23F are 
conjugated to protein D; serotype 18C is conjugated to 
tetanus toxoid carrier protein; and serotype 19F is conju-
gated to diphtheria toxoid carrier protein.
PCV13
PCV13 (Prevnar-13) is a 13-valent pneumococcal poly-
saccharide conjugate vaccine using non-toxic diphtheria 
CRM197 carrier protein. PCV13 is presented as a 0.5 mL 
suspension in a single-dose pre-filled syringe. One dose 
contains approximately 2.2 µg of pneumococcal polysac-
charide from serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 
19F and 23F and 4.4 µg of pneumococcal polysaccharide 
from serotype 6B.
Criteria for discontinuing or modifying allocated interventions
There is no modification of doses for participants in 
this study. If a participant has an allergic or anaphylactic 
response to vaccination, they will be withdrawn from the 
study. Participants may also be withdrawn voluntarily by 
the parent/legal guardian at any time, or by the study staff 
if they refuse any further study procedures or develop any 
of the exclusion criteria during the course of the study.
Strategies to improve and monitor adherence
Scheduled visit dates are noted on a health record card 
kept by the parent. If a participant does not attend a 
scheduled visit, a reminder phone call is made from 
the study clinic. If the participant cannot be contacted 
directly, their local commune health centre is contacted 
for further follow-up by phone or by home visit.
Relevant concomitant care
Participants receive Infanrix-hexa, which is only available 
on the private market, instead of the routine EPI vaccine 
Quinvaxem. Participants in arms A–F receive four doses 
in one of the following schedules: 2, 3, 4 and 19 months 
(arms A and B); 2, 4, 9.5 and 19 months (arms C and E); 
2, 4, 6 and 19 months (arm D); or 2, 3, 4 and 18 months 
(arm F); and participants in arm G receive one dose at 
18 months of age. The routine EPI measles and measles–
rubella immunisations are also provided during the course 
of the study: measles at 9 months of age and measles–
rubella at 18 (arms A–E) or 19 (arms F–G) months of age. 
Participants allocated to one of the 2+1 vaccination sched-
ules (arms C and E) receive measles at 9 months of age 
and receive PCV and Infanrix-hexa 2 weeks later. For visits 
with two vaccinations, the vaccines are administered in 
different limbs. Other vaccinations are permitted in this 
study with a 2-week interval from study vaccines, with the 
exception of Quinvaxem in arms A–F. Other medications 
are also permitted, with the exception of immunosup-
pressive medication and medications listed as contraindi-
cated to the study vaccines.
outcomes
Primary outcome measure
The primary outcome measure is the concentration of 
serotype-specific IgG for the 10 serotypes common to 
both PCV10 and PCV13, assessed 4 weeks post-primary 
series and measured using a modified third-generation 
standardised ELISA.30 Primary comparisons between 
arms are made in terms of the proportion of children 
with antibody concentration ≥0.35 µg/mL for individual 
serotypes. The cut-off of 0.35 µg/mL was determined as 
a result of a pooled analysis of data from efficacy trials31 
and is used as the basis for non-inferiority assessments for 
the approval of new PCVs.32–34
Secondary immunogenicity outcome measures
 ► Serotype-specific IgG antibody concentrations for 
all PCV13 serotypes are measured by ELISA from all 
blood samples (table 1) and are summarised in terms 
of both the proportion of children with antibody 
concentration ≥0.35 µg/mL and the GMC.
 ► Opsonisation indices (OIs) for all PCV13 serotypes 
are measured by opsonophagocytic assay (OPA)35 for 
100 participants per intervention group (arms A–E) 
4 weeks post-primary series and 4 weeks post-booster, 
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and are summarised in terms of the proportion of 
participants with OI ≥8 and the geometric mean titre.
 ► Polysaccharide-specific memory B cells for serotypes 
1, 5, 6B, 14, 18C, 19A and 23F are enumerated by 
ELISPOT35 for 50 participants per intervention group 
(arms A–E) post-booster and at 18 months of age, and 
for 100 participants per control group (arms F and G) 
at 18 and 24 months of age. The results are summa-
rised as the median number of antibody-secreting 
cells.
Nasopharyngeal carriage outcome measures
 ► NP carriage of pneumococcal serotypes is meas-
ured by traditional culture (colonial morphology, 
α-haemolysis, the optochin test and lytA PCR where 
indicated)36 and latex agglutination using type-spe-
cific antisera at 2, 6, 9 and 12 months of age in all 
groups and at 18 and 24 months of age in the control 
groups (arms F and G). NP carriage and density of 
pneumococcal serotypes are measured by quantitative 
real-time PCR (qPCR) targeting lytA and microarray 
at 18 and 24 months of age.37 38 Overall, capsular, 
vaccine-type and serotype-specific carriage rates are 
described. The antimicrobial resistance of pneumo-
coccal isolates is determined at 12 months of age 
by the Clinical and Laboratory Standards Institute 
(CLSI) disk diffusion method, for oxacillin, erythro-
mycin, trimethoprim/sulfamethoxazole, ofloxacin, 
clindamycin, vancomycin, tetracycline and chloram-
phenicol. E-tests are conducted for penicillin, ceftri-
axone and vancomycin where indicated, and CLSI 
breakpoints applied.
 ► NP carriage of H. influenzae is measured by traditional 
culture (colonial morphology, X and V dependence, 
SiaT PCR for discrimination from H. haemolyticus and 
the Phadebact Haemophilus coagglutination test) at 
12 months of age in all groups, at 6 and 9 months of 
age in arms A and C, and from all swabs in the control 
groups (arms F and G). Overall density of H. influ-
enzae carriage is measured by qPCR targeting hpd and 
SiaT diagnostic targets at 18 and 24 months of age.39 40
Immunogenicity of Infanrix-hexa
Immunogenicity of Infanrix-hexa is measured in terms of 
IgG levels to diphtheria, tetanus, Hib PRP antigen, hepa-
titis B surface antigen and Bordetella pertussis. IgG levels 
will be determined by ELISA, using commercial test kits.
An overview of the procedures for collection, trans-
portation and laboratory analyses of the blood and 
NP samples can be found in online supplementary 
appendix 1.
sample size
The target sample size for infant recruitment (groups A–F) 
is 1200 with an allocation ratio of 3:3:5:4:5:4, resulting 
in target group sizes of A=150, B=150, C=250, D=200, 
E=250 and F=200. An additional target of 200 children 
aged 18 months are recruited into group G. Sample size 
calculations are based on the primary outcome of post-pri-
mary series immunogenicity (proportion of participants 
with serotype-specific antibody concentrations ≥0.35 µg/
mL) for each of the two study questions. A non-inferiority 
margin of a 10% difference in absolute risk is deemed 
clinically significant, as used by regulatory authorities. 
Non-inferiority is assessed for each of the 10 serotypes in 
PCV10 (comparing groups A+B with group C or group 
E), and an overall conclusion of non-inferiority is drawn 
if the alternative hypotheses are accepted for at least 7 of 
the 10 serotypes. This sample size provides >99% power 
for the overall conclusion of non-inferiority with a 5% 
one-sided type I error rate, estimated by simulation using 
a tailor-made program written for implementation in 
Stata with 10 000 replications.41 Powers for serotype-spe-
cific hypotheses range from 83% to >99%, calculated in 
PASS Software 2002 using the Farrington-Manning (1990) 
method.42 Based on findings from our earlier work in Fiji 
and from data available in the literature,43–45 the assumed 
probabilities of antibody concentration ≥0.35 µg/mL are 
95% for serotypes 1, 4, 5, 7F, 9V, 14 and 19F; 90% for 
serotype 18C; 80% for serotype 23F; and 75% for serotype 
6B. The within-subject correlation between the multiple 
binary endpoints is captured by a subject-level variation 
term with SD 1.7 in a random-effect logistic regression 
model, and the loss to follow-up rate is assumed to be 5% 
post-primary series and 10% at 12 months of age. The 
sample size also provides 98% power to detect a differ-
ence in post-primary series immunogenicity following two 
doses of PCV10 or PCV13, defined by a 10% difference in 
absolute risk based on Fisher’s exact test (5% two-sided).
Carriage outcomes
The sample size provides 76% and 71% power to detect 
a difference in NTHi carriage rates at 12 months of age 
between groups A and F and groups A and B, respectively, 
and 64% and 59% power to detect a difference in vaccine-
type pneumococcal carriage rates between groups A and 
F and groups A and B, respectively. Difference in carriage 
is defined by a relative risk of 0.6. The calculations were 
based on Fisher’s exact tests (5% one-sided), assuming 
carriage rates in group F (controls) of 30% for NTHi and 
24% for vaccine-type pneumococci, based on data from 
Vietnam (L Yoshida, personal communication).
recruitment
Participants in groups A–F are recruited from infants 
born in the study communes during the enrolment 
period. Commune health centre staff identify poten-
tial participants from the commune health centre birth 
records. Based on the expected number of births, around 
a quarter of infants born in the study communes need 
to be enrolled to complete recruitment within the target 
enrolment period of 12 months. Recruitment rates will 
be monitored on a monthly basis and meetings held with 
study staff and commune health centre staff to discuss 
any significant declines in recruitment rates. Commune 
health centre staff visit the home of potential participants 
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when the infant is approximately 6 weeks old and provide 
verbal and written information about the trial, in Viet-
namese. Those interested in participating are referred to 
the study clinic when the infant is approximately 2 months 
old. At this time, written informed consent is obtained 
(online supplementary appendix 2), after which a study 
nurse/doctor examines the infant to ensure that all the 
eligibility criteria are met. Participants in group G are 
recruited from children turning 18 months old in the 
study communes in parallel to the children in groups A–F 
turning 18 months.
Allocation
The allocation sequence for groups A–F is produced using 
a computer-generated list of random numbers using a 
block randomisation scheme, stratified by district. The 
group allocation is contained within a sealed envelope at 
the study clinic, with sequential ID numbers written on 
the outside of the envelope. The allocation sequence is 
generated at Menzies School of Health Research. A study 
doctor will enrol participants and assign them to a study 
group by selecting the next available envelope. The enve-
lope is not opened until after completion of the informed 
consent and eligibility assessment processes.
blinding
All laboratory staff are blinded to the study group alloca-
tion as the key outcome measures that address the study 
objectives are all laboratory based. Laboratory samples 
are labelled with the ID number, which does not iden-
tify the study group. Given the different timing of the 
vaccination schedules in the different groups, the study 
nurses, vaccine administrators and participants will not 
be blinded to the study group allocation.
data collection methods
Standardised carbon copy data collection forms are used 
and are completed by dedicated, trained study staff. The 
original is transported to the trial office for data entry, 
with the carbon copy filed at the clinic. Blood samples 
and NP swabs are collected by staff specifically trained in 
the collection of samples from infants, and the volume of 
blood collected and the swab quality are recorded.
Retention: Appointments are documented on a parent-
held health record card and a reminder phone call made 
the week before the scheduled visit. If a participant fails 
to attend an appointment, a follow-up phone call is made 
to rebook the visit. Participants are given a small payment 
towards the transport costs of coming to the clinic for 
each study visit. Participants who miss a study visit will 
continue to be followed up for both sample collection 
and vaccine administration where possible, with attempts 
made to contact them until such time as they would have 
completed the study.
data management
Data collection forms are double-entered by dedicated 
data entry staff into pre-coded EpiData V.3.1 files with 
built-in range and consistency checks. Entered data are 
validated monthly and then uploaded to a central Micro-
soft Access database, stored on a secure server. Immu-
nology results are double-entered in a Microsoft Excel 
spreadsheet. NP culture results are entered in a Micro-
soft Access database and qPCR and microarray results 
exported from SentiNET into a Microsoft Excel data-
base. The data collection forms and laboratory results are 
linked at the time of analysis.
statistical methods
Analysis of primary and secondary outcomes
For each of the two study questions, the primary objective 
is to compare a 2+1 schedule of (1) PCV10 and (2) PCV13, 
with a 3+1 schedule of PCV10. The primary outcome is 
the proportion of participants with serotype-specific anti-
body concentrations ≥0.35 µg/mL, 4 weeks post-primary 
series (at 5 months of age). Data from arms A and B are 
combined to form the three-dose post-primary series 
group. The primary analyses assess the non-inferiority of 
(1) two doses of PCV10 at 2 and 4 months of age (arm C) 
compared with three doses at 2, 3 and 4 months of age 
(arms A+B); and (2) two doses of PCV13 at 2 and 4 months 
of age (arm E) compared with three doses of PCV10 at 2, 
3 and 4 months of age (arms A+B). The proportion of 
children achieving protective levels of serotype-specific 
IgG (≥0.35 µg/mL) 4 weeks post-primary series is deter-
mined for each of the 10 PCV10 serotypes. The non-infe-
riority margin is defined by a 10% difference in absolute 
risk. The serotype-specific risk differences (arms A+B/
arm C) with 90% CIs are calculated using the Newcombe 
Score method and the null hypothesis rejected if the 
upper bound of the CI is <10%. Overall non-inferiority 
is declared if at least 7 of the 10 individual null hypoth-
eses are rejected at a one-sided 5% level of significance. 
Secondary data analyses to address the primary objec-
tive include the ratio of GMCs post-primary series (arm 
C/arms A+B and arm E/arms A+B) with 95% CIs, and 
the booster response analysed by analysis of covariance, 
adjusting for pre-booster levels.
Analysis of key secondary objectives for study question 1
 ► A single dose of PCV10 at 2 months of age (arm D) 
will be assessed for non-inferiority to three doses at 2, 
3 and 4 months of age (arms A+B), as described for 
the primary objective.
 ► The impact of a booster dose on pneumococcal and 
NTHi carriage will be assessed at 12 months of age. 
Overall pneumococcal, capsular pneumococcal, 
PCV10 type and NTHi carriage rates will be deter-
mined. Proportions will first be compared between 
the 3+1 group (arm A) and the control group (arm 
F), using Fisher’s exact test. Where significant differ-
ences are found, rates will then be compared between 
the 3+0 group (arm B) and controls and between the 
3+1 and 3+0 groups.
Analysis of key secondary objectives for study question 2
 ► The immunogenicity of two doses of PCV10 or PCV13 
will be compared in relation to the proportion of 
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participants with serotype-specific antibody concen-
trations ≥0.35 µg/mL (to the 10 shared serotypes), 
4 weeks post-primary series (at 5 months of age). 
A significant difference will be indicated by a 10% 
difference in absolute risk, comparing PCV10 (arm C) 
with PCV13 (arm E), and an overall difference will be 
declared if at least 7 of the 10 individual null hypoth-
eses are rejected and the seven differences are in the 
same direction.
 ► The immunogenicity of a single dose of PCV10 or 
PCV13 will be compared, as described for the immu-
nogenicity of two doses.
Additional analyses
Descriptive analyses at the group level will be conducted 
on the OPA, ELISPOT and microarray data.
Populations of analysis
Analyses will be on a per-protocol population. The 
primary non-inferiority analyses will be repeated on an 
intention-to-treat population (ITT), with all participants 
analysed in the group they were randomised to. Any 
differences between the per-protocol and ITT analyses 
will be reported. For each outcome, all available data 
will contribute to the analyses. To investigate whether 
data are missing completely at random, we will explore 
whether attrition varies across the study arms based on 
baseline covariates. If differential attrition is dependent 
on baseline variables, we will use a modelling approach 
to adjust for any such baseline factors and we will present 
the adjusted results along with the primary analysis.
Additional populations of analysis
 ► OPAs will be conducted on a subset of 100 partici-
pants per group. The first 100 participants per group 
with both post-primary series and post-booster blood 
samples available will contribute to the OPA analysis.
 ► B-cell assays will be conducted on a subset of 50 partic-
ipants per group for arms A–E and 100 participants 
per group for arms F and G. The last 50/100 partic-
ipants enrolled per group will have blood samples 
collected for the B-cell analysis.
data monitoring
Data monitoring committee: Safety oversight is under the 
direction of an independent Data Safety and Monitoring 
Board (DSMB), in accordance with a DSMB Charter 
kept in the trial office. The DSMB will meet approxi-
mately three times a year to review aggregate and indi-
vidual participant data related to safety, data integrity and 
overall conduct of the trial, including a detailed review of 
all serious adverse events (SAEs).
Interim analyses and stopping guidelines: No interim 
analyses are planned. Stopping guidelines are based on 
safety. An extraordinary meeting of the DSMB will be 
called in the event that serious safety issues emerge, to 
provide recommendations regarding termination of the 
trial. A final decision to terminate rests with the Principal 
Investigators and the Sponsor.
Harms
Data on SAEs will be collected throughout the study, 
with parents asked about hospitalisations and signifi-
cant signs and symptoms at each study visit and through 
a regular review of hospital records. Details of any SAEs 
will be recorded on the standard reporting form from the 
Vietnam Ministry of Health and reported to the Principal 
Investigators and the Ethics Committees. Participants will 
be kept under observation for 30 min following vaccine 
administration to monitor for any adverse reactions, and 
information on reactogenicity in the 72 hours following 
vaccine administration will be recorded on parent held 
diary cards.
Auditing
External site monitoring will be provided by FHI360, to 
independently assess protocol and good clinical practice 
(GCP) compliance. Monitoring visits will occur at study 
initiation, close-out and approximately twice a year in 
each study clinic. 100% of Informed Consent Forms and 
SAEs and a random selection of approximately 20% of 
participant folders will be monitored, along with the Trial 
Regulatory File and laboratory records.
Patient and public involvement
Patients were not involved in the development, design, 
recruitment or conduct of the study. Community consul-
tation took place at the district level during the design 
phase, as well as discussion and approval of the design 
from the district and city level Ministry of Health and the 
People's Committee of Ho Chi Minh City. Participants 
will be informed of the overall study results by post, with a 
postal address collected at the final study visit.
EtHICs And dIssEMInAtIon
research ethics approval
The protocol, the Plain Language Statement (PLS) and 
the Informed Consent Form (ICF) have approval from 
the Institutional Review Board at the Pasteur Institute 
of Ho Chi Minh City, the Vietnam Ministry of Health 
Ethical Review Committee and the Human Research 
Ethics Committee of the Northern Territory Department 
of Health and the Menzies School of Health Research. 
Both Ethics Committees receive annual reports on the 
trial progress, for continuing approval of the trial.
Protocol amendments
Any modifications to the protocol that may impact on 
the conduct of the study will be documented in a formal 
protocol amendment and approved by both Ethics 
Committees prior to implementation of the changes. The 
modified protocol will be given a new version number 
and date. The Ethics Committees will also be notified of 
any minor corrections/clarifications or administrative 
changes to the protocol, which will be documented in a 
protocol amendment letter. Significant protocol changes 
will also be updated in the  ClinicalTrials. gov record.
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Consent
Obtaining consent
The consent process is undertaken by specifically trained 
study staff. The study staff will go through the PLS and 
ICF, translated into Vietnamese, in detail with the poten-
tial participant's parent/legal guardian. The study staff 
will then discuss the trial further and answer any ques-
tions that may arise. Written informed consent is required 
prior to enrolment of the infant into the study. Consent 
is obtained from the parent/legal guardian as the partic-
ipants are too young to provide consent themselves. A 
copy of the PLS and ICF will be given to the parent/legal 
guardian for their records.
Ancillary studies
Specific consent for the indefinite storage of blood and 
NP samples for future research related to the trial will be 
obtained from the parent/legal guardian and recorded 
on the ICF. Any future research will undergo ethical 
review. Any samples for which indefinite storage is not 
consented to will be destroyed at the close of the trial.
Confidentiality
All study-related information will be stored securely and 
held in strict confidence. All documents kept at the study 
clinics, including the ICFs and participant folders, are 
stored in locked cabinets. All documents kept centrally 
are stored in the trial office, which is kept locked. Elec-
tronic data is stored in the trial office and on a secure 
password protected server. The electronic data and labo-
ratory samples are coded by a unique participant number 
and do not contain the participant name. Access to 
participants’ information will be granted to FHI360 for 
monitoring purposes, and to the Ethics Committees or 
DSMB if required.
Access to data
The final trial dataset will be under the custody of the trial 
sponsor, Murdoch Children’s Research Institute (MCRI). 
The Principal Investigator, trial manager and trial statisti-
cian will have access to the full anonymised final dataset.
Ancillary and post-trial care
Participants are advised to come to the study clinic for 
ancillary care, or to Children’s Hospital Number 2 in Ho 
Chi Minh City, where they will not be charged for treat-
ment and services. All participants are covered by clinical 
trials insurance for trial related harms.
dissemination policy
Plans
Participants will be informed of the overall study results 
by post, with a postal address collected at the final study 
visit. Following completion of the trial, the results will 
be submitted for publication in peer-reviewed journals, 
and presented at relevant international conferences. 
Agreements between MCRI and each of the Pasteur Insti-
tute of Ho Chi Minh City and GSK Biologicals SA provide 
that a party must obtain the prior approval of the other 
parties in advance of submitting a manuscript for publi-
cation, and that such approval will not be unreasonably 
withheld.
Authorship
A publication subcommittee will consider all proposed 
publications, with the final decision on content and 
authorship resting with the Principal Investigator. The 
role of each author will be published. Group authors may 
be used where appropriate. There are no plans for the 
use of professional writers.
Reproducible research
There are no plans to grant public access to the full 
protocol, participant-level dataset or statistical code.
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